HC Wainwright initiated coverage on shares of Maze Therapeutics (NASDAQ:MAZE - Free Report) in a research report report published on Wednesday morning, Marketbeat.com reports. The brokerage issued a buy rating and a $34.00 price target on the stock. HC Wainwright also issued estimates for Maze Therapeutics' Q2 2025 earnings at ($1.15) EPS, Q3 2025 earnings at ($1.06) EPS, Q4 2025 earnings at ($1.07) EPS, FY2025 earnings at ($4.41) EPS, FY2026 earnings at ($3.76) EPS, FY2027 earnings at ($4.07) EPS, FY2028 earnings at ($1.92) EPS and FY2029 earnings at ($1.59) EPS.
A number of other research analysts have also weighed in on MAZE. Wedbush started coverage on shares of Maze Therapeutics in a research note on Tuesday, July 8th. They issued an "outperform" rating and a $17.00 price target on the stock. Guggenheim reiterated a "buy" rating and issued a $19.00 price objective on shares of Maze Therapeutics in a report on Wednesday, April 2nd. Five analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $25.60.
Check Out Our Latest Report on MAZE
Maze Therapeutics Price Performance
Maze Therapeutics stock traded up $0.37 during midday trading on Wednesday, hitting $16.82. 51,167 shares of the stock were exchanged, compared to its average volume of 141,521. The firm has a fifty day moving average price of $13.07. Maze Therapeutics has a 52 week low of $6.71 and a 52 week high of $19.19.
Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($1.15) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.39).
Hedge Funds Weigh In On Maze Therapeutics
Several institutional investors and hedge funds have recently modified their holdings of MAZE. General Catalyst Group Management LLC bought a new stake in Maze Therapeutics during the first quarter worth about $11,405,000. Bessemer Group Inc. acquired a new stake in Maze Therapeutics during the 1st quarter valued at approximately $5,305,000. Bank of New York Mellon Corp acquired a new stake in Maze Therapeutics during the 1st quarter valued at approximately $190,000. New York State Common Retirement Fund acquired a new stake in shares of Maze Therapeutics during the 1st quarter worth approximately $25,000. Finally, Alphabet Inc. acquired a new stake in shares of Maze Therapeutics during the 1st quarter worth approximately $26,561,000.
About Maze Therapeutics
(
Get Free Report)
We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.
Further Reading
Before you consider Maze Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maze Therapeutics wasn't on the list.
While Maze Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access